JPH02194A - ヒト血清アルブミンのｎ‐未端を含有するポリペプチド - Google Patents

ヒト血清アルブミンのｎ‐未端を含有するポリペプチド

Info

Publication number: JPH02194A
Authority: JP; Japan
Prior art keywords: hsa; nucleotide sequence; polypeptide; serum albumin; human serum
Prior art date: 1987-10-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP63272005A

Other languages

English (en)

Japanese (ja)

Inventor

David J Ballance

ディビッド　ジェイムズ　バランス

Edward Hinchliffe

エドワード　ヒンクリフ

Michael J Geisow

マイケル　ジョン　ゲイソー

Peter J Senior

ピーター　ジェイムズ　シニア

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Albumedix Ltd

Original Assignee

Delta Biotechnology Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-10-30

Filing date

1988-10-29

Publication date

1990-01-05

1988-10-29 Application filed by Delta Biotechnology Ltd filed Critical Delta Biotechnology Ltd

1990-01-05 Publication of JPH02194A publication Critical patent/JPH02194A/ja

Status Pending legal-status Critical Current

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 28
229920001184 polypeptide Polymers 0.000 title claims abstract description 25
102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 25
108091006905 Human Serum Albumin Proteins 0.000 title claims abstract description 12
102000008100 Human Serum Albumin Human genes 0.000 title claims abstract description 12
239000002773 nucleotide Substances 0.000 claims abstract description 12
125000003729 nucleotide group Chemical group 0.000 claims abstract description 12
108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 6
125000000539 amino acid group Chemical group 0.000 claims abstract description 6
239000013598 vector Substances 0.000 claims abstract description 6
230000009466 transformation Effects 0.000 claims abstract description 5
238000004519 manufacturing process Methods 0.000 claims description 12
240000004808 Saccharomyces cerevisiae Species 0.000 claims description 10
235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 10
239000000203 mixture Substances 0.000 claims description 8
244000005700 microbiome Species 0.000 claims description 5
238000012258 culturing Methods 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 1
238000000034 method Methods 0.000 abstract description 13
239000003058 plasma substitute Substances 0.000 abstract description 4
239000000463 material Substances 0.000 abstract description 3
230000008569 process Effects 0.000 abstract description 3
239000013604 expression vector Substances 0.000 abstract description 2
239000005445 natural material Substances 0.000 abstract 1
BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 16
108020004705 Codon Proteins 0.000 description 15
235000001014 amino acid Nutrition 0.000 description 15
229940024606 amino acid Drugs 0.000 description 15
239000013612 plasmid Substances 0.000 description 15
108090000623 proteins and genes Proteins 0.000 description 15
235000018102 proteins Nutrition 0.000 description 13
102000004169 proteins and genes Human genes 0.000 description 13
150000001413 amino acids Chemical class 0.000 description 12
150000001875 compounds Chemical class 0.000 description 12
239000012634 fragment Substances 0.000 description 11
102000009027 Albumins Human genes 0.000 description 8
108010088751 Albumins Proteins 0.000 description 8
108091034117 Oligonucleotide Proteins 0.000 description 8
125000003275 alpha amino acid group Chemical group 0.000 description 7
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
108091026890 Coding region Proteins 0.000 description 5
210000004899 c-terminal region Anatomy 0.000 description 5
210000004027 cell Anatomy 0.000 description 5
229930014626 natural product Natural products 0.000 description 5
108020004414 DNA Proteins 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 4
241000282414 Homo sapiens Species 0.000 description 4
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
238000012300 Sequence Analysis Methods 0.000 description 4
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
239000004472 Lysine Substances 0.000 description 3
108020004511 Recombinant DNA Proteins 0.000 description 3
230000008901 benefit Effects 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
230000002016 colloidosmotic effect Effects 0.000 description 3
239000012141 concentrate Substances 0.000 description 3
239000012228 culture supernatant Substances 0.000 description 3
239000002609 medium Substances 0.000 description 3
230000003204 osmotic effect Effects 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
230000028327 secretion Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
235000009582 asparagine Nutrition 0.000 description 2
229960001230 asparagine Drugs 0.000 description 2
230000001925 catabolic effect Effects 0.000 description 2
239000000084 colloidal system Substances 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
230000007515 enzymatic degradation Effects 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
235000013922 glutamic acid Nutrition 0.000 description 2
239000004220 glutamic acid Substances 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
238000010647 peptide synthesis reaction Methods 0.000 description 2
230000017854 proteolysis Effects 0.000 description 2
230000002797 proteolythic effect Effects 0.000 description 2
LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
238000011160 research Methods 0.000 description 2
239000012266 salt solution Substances 0.000 description 2
238000000926 separation method Methods 0.000 description 2
230000035939 shock Effects 0.000 description 2
229940079710 sodium acetyltryptophanate Drugs 0.000 description 2
UQSHZBSQKMVQBS-UHFFFAOYSA-M sodium;2-acetamido-3-(1h-indol-3-yl)propanoate Chemical compound [Na+].C1=CC=C2C(CC(NC(=O)C)C([O-])=O)=CNC2=C1 UQSHZBSQKMVQBS-UHFFFAOYSA-M 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
239000011573 trace mineral Substances 0.000 description 2
235000013619 trace mineral Nutrition 0.000 description 2
241001515965 unidentified phage Species 0.000 description 2
239000004474 valine Substances 0.000 description 2
239000011782 vitamin Substances 0.000 description 2
229940088594 vitamin Drugs 0.000 description 2
235000013343 vitamin Nutrition 0.000 description 2
229930003231 vitamin Natural products 0.000 description 2
150000003722 vitamin derivatives Chemical class 0.000 description 2
-1 1.2 g/l! Chemical compound 0.000 description 1
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
208000007788 Acute Liver Failure Diseases 0.000 description 1
206010000804 Acute hepatic failure Diseases 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
244000063299 Bacillus subtilis Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
241000537222 Betabaculovirus Species 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
101100148606 Caenorhabditis elegans pst-1 gene Proteins 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102000004594 DNA Polymerase I Human genes 0.000 description 1
108010017826 DNA Polymerase I Proteins 0.000 description 1
108010076804 DNA Restriction Enzymes Proteins 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
230000005526 G1 to G0 transition Effects 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
206010018910 Haemolysis Diseases 0.000 description 1
101000658545 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Type I restriction enyme HindI endonuclease subunit Proteins 0.000 description 1
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000829958 Homo sapiens N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Proteins 0.000 description 1
UWBDLNOCIDGPQE-GUBZILKMSA-N Ile-Lys Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN UWBDLNOCIDGPQE-GUBZILKMSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241001430197 Mollicutes Species 0.000 description 1
102100023315 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Human genes 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
239000001888 Peptone Substances 0.000 description 1
108010080698 Peptones Proteins 0.000 description 1
NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
108010071690 Prealbumin Proteins 0.000 description 1
102000007584 Prealbumin Human genes 0.000 description 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
231100000836 acute liver failure Toxicity 0.000 description 1
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
229960002079 calcium pantothenate Drugs 0.000 description 1
229940041514 candida albicans extract Drugs 0.000 description 1
230000002612 cardiopulmonary effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000009585 enzyme analysis Methods 0.000 description 1
208000014205 familial febrile seizures Diseases 0.000 description 1
239000012527 feed solution Substances 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
239000006260 foam Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
230000004927 fusion Effects 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000012252 genetic analysis Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
150000003278 haem Chemical class 0.000 description 1
230000008588 hemolysis Effects 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
229960000367 inositol Drugs 0.000 description 1
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000009249 intrinsic sympathomimetic activity Effects 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
239000003446 ligand Substances 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
238000013507 mapping Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
229960003512 nicotinic acid Drugs 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
235000019319 peptone Nutrition 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
102000054765 polymorphisms of proteins Human genes 0.000 description 1
229910001414 potassium ion Inorganic materials 0.000 description 1
235000008160 pyridoxine Nutrition 0.000 description 1
239000011677 pyridoxine Substances 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000007017 scission Effects 0.000 description 1
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229960005480 sodium caprylate Drugs 0.000 description 1
229910001415 sodium ion Inorganic materials 0.000 description 1
BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
235000019157 thiamine Nutrition 0.000 description 1
239000011721 thiamine Substances 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
230000001810 trypsinlike Effects 0.000 description 1
229940011671 vitamin b6 Drugs 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1
238000004383 yellowing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Zoology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Pulmonology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Materials For Medical Uses (AREA)

JP63272005A 1987-10-30 1988-10-29 ヒト血清アルブミンのｎ‐未端を含有するポリペプチド Pending JPH02194A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB8725529		1987-10-30
GB878725529A GB8725529D0 (en)	1987-10-30	1987-10-30	Polypeptides

Publications (1)

Publication Number	Publication Date
JPH02194A true JPH02194A (ja)	1990-01-05

Family

ID=10626211

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP63272005A Pending JPH02194A (ja)	1987-10-30	1988-10-29	ヒト血清アルブミンのｎ‐未端を含有するポリペプチド

Country Status (17)

Country	Link
US (1)	US5380712A (fr)
EP (1)	EP0322094B1 (fr)
JP (1)	JPH02194A (fr)
KR (1)	KR0153516B1 (fr)
AT (1)	ATE82858T1 (fr)
AU (1)	AU619768B2 (fr)
CA (1)	CA1341298C (fr)
DE (1)	DE3876401T2 (fr)
DK (1)	DK175046B1 (fr)
ES (1)	ES2053758T3 (fr)
FI (1)	FI101381B (fr)
GB (1)	GB8725529D0 (fr)
GR (1)	GR3007162T3 (fr)
HU (1)	HU209145B (fr)
IE (1)	IE61050B1 (fr)
IL (1)	IL88223A (fr)
ZA (1)	ZA888118B (fr)

Families Citing this family (179)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5225538A (en) *	1989-02-23	1993-07-06	Genentech, Inc.	Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) *	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
US6406697B1 (en)	1989-02-23	2002-06-18	Genentech, Inc.	Hybrid immunoglobulins
US5766883A (en) *	1989-04-29	1998-06-16	Delta Biotechnology Limited	Polypeptides
GB8909916D0 (en) *	1989-04-29	1989-06-14	Delta Biotechnology Ltd	Polypeptides
ATE92107T1 (de) *	1989-04-29	1993-08-15	Delta Biotechnology Ltd	N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
GB8927480D0 (en) *	1989-12-05	1990-02-07	Delta Biotechnology Ltd	Mutant fungal strain detection and new promoter
US5993805A (en)	1991-04-10	1999-11-30	Quadrant Healthcare (Uk) Limited	Spray-dried microparticles and their use as therapeutic vehicles
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5698517A (en) *	1994-03-21	1997-12-16	University Of Hawaii, Office Of Technology Transfer And Economic Development	Thyroxin-binding HSA fragments
DE4436352A1 (de) *	1994-10-12	1996-04-18	Kay Brune	Verfahren zur diagnostischen Beurteilung und Verlaufskontrolle sowie Arzneimittel zur Therapie von Schockzuständen beim Menschen
US5674842A (en) *	1994-10-26	1997-10-07	Health Research, Incorporated	Growth inhibitory peptide
US7820798B2 (en)	1994-11-07	2010-10-26	Human Genome Sciences, Inc.	Tumor necrosis factor-gamma
US7597886B2 (en)	1994-11-07	2009-10-06	Human Genome Sciences, Inc.	Tumor necrosis factor-gamma
US5723125A (en) *	1995-12-28	1998-03-03	Tanox Biosystems, Inc.	Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
GB9526733D0 (en)	1995-12-30	1996-02-28	Delta Biotechnology Ltd	Fusion proteins
US7888466B2 (en)	1996-01-11	2011-02-15	Human Genome Sciences, Inc.	Human G-protein chemokine receptor HSATU68
EP0947581A4 (fr) *	1996-08-08	2004-07-28	Mitsubishi Pharma Corp	Milieu de culture et ses applications
US6274305B1 (en)	1996-12-19	2001-08-14	Tufts University	Inhibiting proliferation of cancer cells
GB9815909D0 (en)	1998-07-21	1998-09-16	Btg Int Ltd	Antibody preparation
JP2002534059A (ja) *	1998-10-13	2002-10-15	ザユニバーシティオブジョージアリサーチファウンデーション，インコーポレイティド	安定化された生物活性ペプチドおよび同定、合成および使用方法
US20030190740A1 (en) *	1998-10-13	2003-10-09	The University Of Georgia Research Foundation, Inc	Stabilized bioactive peptides and methods of identification, synthesis, and use
US6926898B2 (en)	2000-04-12	2005-08-09	Human Genome Sciences, Inc.	Albumin fusion proteins
US6946134B1 (en)	2000-04-12	2005-09-20	Human Genome Sciences, Inc.	Albumin fusion proteins
US20050100991A1 (en) *	2001-04-12	2005-05-12	Human Genome Sciences, Inc.	Albumin fusion proteins
US20030031675A1 (en)	2000-06-06	2003-02-13	Mikesell Glen E.	B7-related nucleic acids and polypeptides useful for immunomodulation
AU2001268427B2 (en)	2000-06-16	2007-03-29	Glaxosmithkline Intellectual Property Limited	Antibodies that immunospecifically bind to blys
WO2002022685A2 (fr) *	2000-09-11	2002-03-21	Kufe Donald W	Domaine extracellulaire du muc1 et compositions et procedes pour le traitement du cancer derives de celui-ci
SI1724284T1 (sl)	2000-12-07	2009-12-31	Lilly Co Eli	Glp-1 fuzijski proteini
WO2002058450A2 (fr) *	2000-12-22	2002-08-01	Dana-Faber Cancer Institute, Inc.	Regulation de la proliferation cellulaire par muc1
US20050054051A1 (en) *	2001-04-12	2005-03-10	Human Genome Sciences, Inc.	Albumin fusion proteins
US20050244931A1 (en) *	2001-04-12	2005-11-03	Human Genome Sciences, Inc.	Albumin fusion proteins
US7507413B2 (en)	2001-04-12	2009-03-24	Human Genome Sciences, Inc.	Albumin fusion proteins
US20060084794A1 (en) *	2001-04-12	2006-04-20	Human Genome Sciences, Inc.	Albumin fusion proteins
JP2004536579A (ja)	2001-04-13	2004-12-09	ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド	血管内皮増殖因子２
MXPA03010747A (es)	2001-05-25	2004-03-02	Human Genome Sciences Inc	Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
WO2003030821A2 (fr) *	2001-10-05	2003-04-17	Human Genome Sciences, Inc.	Proteines de fusion d'albumine
EP2292273A3 (fr)	2001-10-10	2011-11-23	BioGeneriX AG	Remodelage et Glycoconjugaison de Peptides
US20080194481A1 (en)	2001-12-21	2008-08-14	Human Genome Sciences, Inc.	Albumin Fusion Proteins
WO2005003296A2 (fr)	2003-01-22	2005-01-13	Human Genome Sciences, Inc.	Proteines hybrides d'albumine
CA2841097A1 (fr)	2001-12-21	2003-07-24	Human Genome Sciences, Inc.	Albumine et proteines hybrides g-csf
WO2003059934A2 (fr)	2001-12-21	2003-07-24	Human Genome Sciences, Inc.	Proteines de fusion d'albumine
US20060122374A1 (en)	2002-02-07	2006-06-08	Peter Mertins	Albumin-fused anti-angiogenesis peptides
US20060002935A1 (en)	2002-06-28	2006-01-05	Domantis Limited	Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
GB0217033D0 (en)	2002-07-23	2002-08-28	Delta Biotechnology Ltd	Gene and polypeptide sequences
NZ540194A (en)	2002-11-08	2008-07-31	Ablynx Nv	Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
CA2522345A1 (fr)	2003-04-09	2004-11-18	Neose Technologies, Inc.	Methode de glycopegylation et proteines/peptides produits au moyen de ces methodes
US20080090770A1 (en) *	2003-04-11	2008-04-17	Belmares Michael P	Modulation of Muc1 Mediated Signal Transduction
WO2005042573A1 (fr) *	2003-10-24	2005-05-12	Dana-Farber Cancer Institute, Inc.	Modulation de l'interaction de muc1 avec des ligands de muc1
CN102816241B (zh)	2004-02-09	2015-07-22	人类基因科学公司	清蛋白融合蛋白
EP1718367A1 (fr) *	2004-02-23	2006-11-08	Genzyme Corporation	Stimulation de l'apoptose declenchee par le ligand du recepteur de mort par l'antagoniste de muc1
EP1786463A4 (fr)	2004-03-26	2009-05-20	Human Genome Sciences Inc	Anticorps contre le recepteur nogo
WO2006034455A2 (fr)	2004-09-23	2006-03-30	Vasgene Therapeutics, Inc.	Composes de polypeptides pour l'inhibition de l'angiogenese et de croissance tumorale
KR20070084069A (ko)	2004-10-08	2007-08-24	도만티스 리미티드	Ｔｎｆｒ1에 대한 단일 도메인 항체 및 이의 사용 방법
KR20080074120A (ko)	2005-10-13	2008-08-12	휴먼 게놈 사이언시즈, 인코포레이티드	자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
WO2008019368A2 (fr)	2006-08-07	2008-02-14	Teva Biopharmaceuticals Usa, Inc.	Protéines de fusion d'albumine et d'insuline
KR20090060294A (ko)	2006-09-08	2009-06-11	암브룩스, 인코포레이티드	변형된 인간 혈장 폴리펩티드 또는 Ｆｃ 스캐폴드 및 그의 용도
EP2423220B1 (fr)	2007-01-30	2015-04-29	Epivax, Inc.	Épitopes de lymphocytes t régulateurs, compositions et utilisations de ceux-ci
WO2008097840A2 (fr)	2007-02-02	2008-08-14	Dana-Farber Cancer Institute, Inc.	Méthodes et compositions associées à la régulation de muc1 par hsf1 et stat3
WO2008097844A2 (fr) *	2007-02-02	2008-08-14	Dana -Farber Cancer Institute, Inc.	Méthodes et compositions associées à la régulation de l'apoptose par des protéines muc1 et des protéines pro-apoptotiques contenant seulement le domaine bh3
WO2008127094A2 (fr)	2007-04-12	2008-10-23	Stichting Katholieke Universiteit, More Particularly The Radboud University Nijmegen Medical Center	Nouveaux facteurs de virulence de streptococcus pneumoniae
KR101426667B1 (ko)	2007-04-17	2014-08-06	스티칭 디엔스트 랜드보위쿤디그 온데조에크	비-포유동물 글리코실트랜스퍼라제의 발현에 의한 식물에서의 포유동물형 글리코실화
CN101675071B (zh)	2007-05-02	2014-06-18	Ambrx公司	经修饰干扰素β多肽和其用途
CA2688434A1 (fr)	2007-06-06	2008-12-11	Domantis Limited	Polypeptides, domaines variables d'anticorps et antagonistes
AR068767A1 (es)	2007-10-12	2009-12-02	Novartis Ag	Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
CA2703830A1 (fr)	2007-11-20	2009-05-28	Ambrx, Inc.	Polypeptides d'insuline modifies et leurs utilisations
EP2318029B1 (fr)	2008-07-23	2017-11-01	Ambrx, Inc.	Polypeptides g-csf bovins modifiés et leurs utilisations
EP2174664A1 (fr)	2008-10-07	2010-04-14	Stichting Katholieke Universiteit, more particularly the Radboud University Nijmegen Medical Centre	Nouveaux facteurs de virulence de la pneumonie à streptocoques
IT1392551B1 (it) *	2008-11-25	2012-03-09	Bioindustry Park Del Canavese S P A	Biomarcatori per la diagnosi e per rilevare la progressione di malattie neurodegenerative, in particolare della sclerosi laterale amiotrofica
CN102307897B (zh)	2008-12-05	2016-01-20	葛兰素集团有限公司	选出蛋白酶抗性多肽的方法
SG172789A1 (en)	2009-02-11	2011-08-29	Novozymes Biopharma Dk As	Albumin variants and conjugates
MX2011008799A (es)	2009-02-19	2011-09-27	Glaxo Group Ltd	Polipeptidos, dominios variables de anticuerpos, y antagonistas anti-tnfr1 mejorados.
CA2759942A1 (fr)	2009-04-27	2010-10-07	Novartis Ag	Composition et procedes d'utilisation d'anticorps therapeutiques specifiques du sous-motif beta-1 des recepteurs d'il-12
ES2655877T3 (es)	2009-04-27	2018-02-22	Novartis Ag	Composiciones y métodos para aumentar el crecimiento muscular
JP2012532619A (ja)	2009-07-16	2012-12-20	グラクソグループリミテッド	Ｔｎｆｒ１を部分的に阻害するためのアンタゴニスト、用途および方法
WO2011029823A1 (fr)	2009-09-09	2011-03-17	Novartis Ag	Anticorps monoclonal réactif avec cd63 lors de son expression à la surface de mastocytes dégranulés
AR078763A1 (es)	2009-10-27	2011-11-30	Glaxo Group Ltd	Polipeptidos anti factor de necrosis tumoral 1 (anti-tnfr1) estables, dominios variables de anticuerpos y antagonistas
AU2010311332B2 (en)	2009-10-30	2015-04-23	Albumedix Ltd.	Albumin variants
GB0919054D0 (en)	2009-10-30	2009-12-16	Isis Innovation	Treatment of obesity
GB0919837D0 (en)	2009-11-13	2009-12-30	Isis Innovation	Method of treatment and screening method
JP2013515081A (ja)	2009-12-21	2013-05-02	アンブルックス，インコーポレイテッド	修飾されているブタのソマトトロピンポリペプチドおよびそれらの使用
EA201290541A1 (ru)	2009-12-21	2013-05-30	Амбркс, Инк.	Модифицированные бычьи соматотропиновые полипептиды и их применение
ES2557431T3 (es)	2010-02-23	2016-01-26	Stichting Katholieke Universiteit	Vacuna de combinación para Streptococcus
KR20130070576A (ko)	2010-04-09	2013-06-27	노보자임스 바이오파마 디케이 에이/에스	알부민 유도체 및 변이체
PE20140160A1 (es)	2010-08-17	2014-02-08	Ambrx Inc	Polipeptidos de relaxina modificados y sus usos
EP2625203A1 (fr)	2010-10-05	2013-08-14	Novartis AG	Anticorps anti-il12rbêta1 et leur utilisation dans le traitement des troubles auto-immuns et inflammatoires
US9783601B2 (en)	2010-12-01	2017-10-10	Alderbio Holdings Llc	Methods of preventing inflammation and treating pain using anti-NGF compositions
AU2012222833B2 (en)	2011-03-03	2017-03-16	Zymeworks Inc.	Multivalent heteromultimer scaffold design and constructs
NO2707391T3 (fr)	2011-05-13	2018-04-07
CN108014334B (zh)	2011-05-20	2021-11-30	H.伦德贝克公司	抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
PT3495392T (pt)	2011-05-20	2021-09-22	H Lundbeck As	Composições anti-cgrp e a sua utilização
EA033109B1 (ru)	2011-05-20	2019-08-30	Олдербайо Холдингз Ллк	Способы ингибирования, профилактики или лечения диареи и/или поддержания соответствующих уровней электролитов и жидкости в толстой кишке субъекта, подвергающегося связанному с диареей состоянию, с помощью антитела против cgrp или фрагмента антитела против cgrp
WO2012175691A1 (fr)	2011-06-22	2012-12-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anticorps anti-axl et utilisations associées
AU2012273955A1 (en)	2011-06-22	2014-01-09	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Anti-Axl antibodies and uses thereof
AU2012280474A1 (en)	2011-07-01	2014-01-16	Bayer Intellectual Property Gmbh	Relaxin fusion polypeptides and uses thereof
JP6472999B2 (ja)	2011-07-01	2019-02-20	ノバルティスアーゲー	代謝障害を治療するための方法
AU2012283235A1 (en)	2011-07-08	2014-01-09	Bayer Intellectual Property Gmbh	Fusion proteins releasing Relaxin and uses thereof
EP2742947B1 (fr) *	2011-08-10	2016-11-30	Nipro Corporation	Activateur d'excrétion de bilirubine
HK1200842A1 (en)	2011-11-18	2015-08-14	Albumedix Ltd	Proteins with improved half-life and other properties
EP3330283A3 (fr)	2012-03-16	2018-07-11	Albumedix A/S	Variants d'albumine
EP2851429B1 (fr)	2012-05-18	2019-07-24	Adda Biotech Inc.	Protéine et conjugué protéique pour le traitement du diabète et applications associées
IN2015DN01115A (fr)	2012-07-13	2015-06-26	Zymeworks Inc
US9376489B2 (en)	2012-09-07	2016-06-28	Novartis Ag	IL-18 binding molecules
CA2890766A1 (fr)	2012-11-08	2014-05-15	Novozymes Biopharma Dk A/S	Variants d'albumine
LT2953969T (lt)	2013-02-08	2019-12-10	Novartis Ag	Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui
US20160152686A1 (en)	2013-03-13	2016-06-02	Bristol-Myers Squibb Company	Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto
US20150017166A1 (en)	2013-07-03	2015-01-15	Alderbio Holdings Llc	Regulation of glucose metabolism using anti-cgrp antibodies
WO2015022658A2 (fr)	2013-08-14	2015-02-19	Novartis Ag	Procédé de traitement de la myosite à corps d'inclusion sporadique
WO2015067986A1 (fr)	2013-11-07	2015-05-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anticorps allosteriques de la neureguline, diriges contre her3
WO2015081891A1 (fr)	2013-12-06	2015-06-11	Baikang (Suzhou) Co., Ltd	Pro-fragments bioréversibles pour médicaments contenant de l'azote et de l'hydroxyle
JP6865584B2 (ja) *	2013-12-23	2021-04-28	コヴァラブ	化合物の共有結合性コンジュゲーションのためのｍＴＧ基質
CA3265373A1 (fr)	2014-02-20	2025-10-30	H. Lundbeck A/S	Anticorps anti-acth et leur utilisation
TW201622746A (zh)	2014-04-24	2016-07-01	諾華公司	改善或加速髖部骨折術後身體復原之方法
EP3157947A1 (fr)	2014-06-23	2017-04-26	Novartis AG	Polypeptide de fusion hsa-gdf-15 et son utilisation
EP3161001A2 (fr)	2014-06-25	2017-05-03	Novartis AG	Anticorps spécifiques pour il-17a fusé à des étiquettes de peptide de liaison hyaluronan
EP3221349B1 (fr)	2014-11-19	2020-11-04	Axon Neuroscience SE	Anticorps anti-tau humanisés dans la maladie d'alzheimer
EP3229836B1 (fr)	2014-12-09	2019-11-13	Institut National de la Sante et de la Recherche Medicale (INSERM)	Anticoprs monoclonaux contre 'axl'
EP3233916A4 (fr)	2014-12-19	2018-06-06	Alder Biopharmaceuticals, Inc.	Anticorps anti-acth humanisés et leur utilisation
NL2014148B1 (en)	2015-01-16	2017-01-05	Univ Erasmus Med Ct Rotterdam	Combination vaccine for camelids.
WO2016135041A1 (fr)	2015-02-26	2016-09-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Protéines de fusion et anticorps les contenant pour favoriser l'apoptose
EP3298140B1 (fr)	2015-05-19	2024-04-24	Yale University	Compositions pour le traitement d'états de calcification pathologique, et méthodes les utilisant
WO2016188911A1 (fr)	2015-05-22	2016-12-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Fragments d'anticorps monoclonaux humains inhibant à la fois l'activité catalytique de cath-d et sa liaison au récepteur lrp1
US10940204B2 (en)	2015-07-31	2021-03-09	Research Institute At Nationwide Children's Hospital	Peptides and antibodies for the removal of biofilms
BR112018003179A2 (pt)	2015-08-20	2018-09-25	Albumedix As	conjugados e variantes de albumina
EP3365027B1 (fr)	2015-10-14	2022-03-30	Research Institute at Nationwide Children's Hospital	Anticorps spécifiques interférant avec hu et leur utilisation comme inhibiteur de biofilm
EP3368571B1 (fr)	2015-10-30	2022-12-07	The Regents of The University of California	Polypeptides sensibles au facteur de croissance transformant bêta et leurs procédés d'utilisation
US20190000923A1 (en)	2015-12-22	2019-01-03	Novartis Ag	Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
KR102438140B1 (ko)	2016-03-22	2022-08-31	엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔	인간화 항-클라우딘-1 항체 및 이의 용도
SG10202109691UA (en)	2016-04-15	2021-10-28	Alder Biopharmaceuticals Inc	Anti-pacap antibodies and uses thereof
EP3491022B1 (fr)	2016-07-29	2025-09-10	Institut National de la Santé et de la Recherche Médicale (INSERM)	Anticorps ciblant des macrophages associés aux tumeurs et leurs utilisations
CA3039136A1 (fr)	2016-09-02	2018-03-08	The Regents Of The University Of California	Methodes et compositions impliquant des fragments variables a chaine unique (scfv) de liaison au recepteur alpha de l'interleukine-6
EP3565589A1 (fr)	2017-01-04	2019-11-13	Research Institute at Nationwide Children's Hospital	Anticorps et vaccins dnabii présentant une activité améliorée
AU2018206560B9 (en)	2017-01-04	2025-04-03	Research Institute At Nationwide Children's Hospital	Antibody fragments for the treatment of biofilm-related disorders
US11274160B2 (en)	2017-03-02	2022-03-15	INSERM (Institut National de la Santé et de la Recherche Médicale	Antibodies having specificity to Nectin-4 and uses thereof
EP3595445B1 (fr)	2017-03-15	2024-09-04	The Research Institute at Nationwide Children's Hospital	Composition et procédés de rupture de biofilms bactériens sans inflammation associée
KR102628323B1 (ko)	2017-03-24	2024-01-22	노바르티스 아게	심장질환 예방 및 치료 방법
UY37758A (es)	2017-06-12	2019-01-31	Novartis Ag	Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
EP3645564A1 (fr)	2017-06-28	2020-05-06	Novartis AG	Procédé de prévention et de traitement de l'incontinence urinaire
CN111727075B (zh)	2017-11-27	2024-04-05	普渡制药公司	靶向人组织因子的人源化抗体
EP3552631A1 (fr)	2018-04-10	2019-10-16	Inatherys	Conjugués d'anticorps-médicament et leurs utilisations pour le traitement du cancer
US20210139610A1 (en)	2018-06-29	2021-05-13	Research Institute At Nationwide Children's Hospital	Compositions and methods for mediating eps
WO2020053122A1 (fr)	2018-09-10	2020-03-19	INSERM (Institut National de la Santé et de la Recherche Médicale)	Combinaison d'anticorps her2/neu avec de l'hème pour le traitement du cancer
CN112771074A (zh)	2018-10-05	2021-05-07	国家儿童医院研究所	用于酶促破坏细菌生物膜的组合物和方法
US20220098252A1 (en)	2019-01-25	2022-03-31	Ospedale San Raffaele S.R.L.	Inhibitor of dux4 and uses thereof
EP3947446A1 (fr)	2019-03-25	2022-02-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Traitement de troubles de tauopathie par ciblage de nouvelles espèces tau
PH12021553101A1 (en)	2019-06-12	2023-10-02	Novartis Ag	Natriuretic peptide receptor 1 antibodies and methods of use
CA3145385A1 (fr)	2019-07-08	2021-01-14	Steven D. Goodman	Compositions d'anticorps pour detruire des biofilms
WO2021058729A1 (fr)	2019-09-27	2021-04-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anticorps dirigés contre le récepteur de type i d'une substance inhibitrice anti-mullérienne et leurs utilisations
US12441788B2 (en)	2019-09-27	2025-10-14	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Anti-müllerian inhibiting substance antibodies and uses thereof
US20210147525A1 (en)	2019-10-18	2021-05-20	The Regents Of The University Of California	Methods and compositions for treating pathogenic blood vessel disorders
EP4072682A1 (fr)	2019-12-09	2022-10-19	Institut National de la Santé et de la Recherche Médicale (INSERM)	Anticorps présentant une spécificité pour her4 et leurs utilisations
EP4087863A1 (fr)	2020-01-10	2022-11-16	Institut National de la Santé et de la Recherche Médicale (INSERM)	Protéines rspo1 et leur utilisation
US12629445B2 (en)	2020-03-20	2026-05-19	Bard Peripheral Vascular, Inc.	Reactive hydrogel forming formulations and related methods, including methods of preparation
KR20210124867A (ko)	2020-04-06	2021-10-15	하. 룬드벡 아크티에셀스카브	항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료
EP4149558A1 (fr)	2020-05-12	2023-03-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	Nouveau procédé de traitement de lymphomes cutanés à lymphocytes t et de lymphomes dérivés de tfh
WO2022002880A1 (fr)	2020-06-29	2022-01-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anticorps à domaine unique anti-protéine s et polypeptides les comprenant
US11739166B2 (en)	2020-07-02	2023-08-29	Davol Inc.	Reactive polysaccharide-based hemostatic agent
US12161777B2 (en)	2020-07-02	2024-12-10	Davol Inc.	Flowable hemostatic suspension
EP4259661A1 (fr)	2020-12-14	2023-10-18	Novartis AG	Agents d'inversion de liaison pour anticorps anti-récepteur 1 du peptide natriurétique (npr1) et leurs utilisations
WO2022146917A1 (fr)	2020-12-28	2022-07-07	Davol Inc.	Matériaux hémostatiques pulvérulents secs réactifs comprenant une protéine et un agent de réticulation à base de polyéthylène glycol modifié multifonctionnalisé
WO2022269451A1 (fr)	2021-06-22	2022-12-29	Novartis Ag	Anticorps bispécifiques destinés à être utilisés dans le traitement de l'hidrosadénite suppurée
IL310154A (en)	2021-07-15	2024-03-01	Diogenx	Recombinant variants of r-spondin proteins and their use
CN117813325A (zh)	2021-08-27	2024-04-02	H.隆德贝克有限公司	使用抗cgrp抗体治疗丛集性头痛
AU2023231442B2 (en)	2022-03-11	2026-07-02	Mablink Bioscience	Antibody-drug conjugates and their uses
JP2025510997A (ja)	2022-03-30	2025-04-15	ノバルティスアーゲー	抗ナトリウム利尿ペプチド受容体１（ｎｐｒ１）抗体を使用して障害を治療する方法
EP4584291A1 (fr)	2022-09-08	2025-07-16	Institut National de la Santé et de la Recherche Médicale	Anticorps présentant une spécificité pour ltbp2 et leurs utilisations
WO2024056668A1 (fr)	2022-09-12	2024-03-21	Institut National de la Santé et de la Recherche Médicale	Nouveaux anticorps anti-itgb8 et leurs utilisations
EP4389762A1 (fr)	2022-12-23	2024-06-26	Ospedale San Raffaele S.r.l.	Inhibiteurs de l'activité de dux4 et leur utilisation en thérapie.
AU2024210262A1 (en)	2023-01-19	2025-07-10	Centre National De La Recherche Scientifique	Recombinant variants of r-spondin proteins and their use
IL322653A (en)	2023-02-14	2025-10-01	H Lundbeck As	Treating pain caused by opioids
AU2024245676A1 (en)	2023-03-30	2025-10-09	272BIO Limited	Gnrh-binding polypeptides and uses thereof
WO2024236156A1 (fr)	2023-05-17	2024-11-21	Institut National de la Santé et de la Recherche Médicale	Anticorps anti-cathepsine d
EP4477236A1 (fr)	2023-06-14	2024-12-18	Inatherys	Polythérapie pour le traitement d'une tumeur à l'aide d'un adc comprenant des anticorps anti-cd71 et des mimétiques bh3
AU2024313073A1 (en)	2023-06-23	2026-02-12	H. Lundbeck A/S	Combinational treatment
WO2025012417A1 (fr)	2023-07-13	2025-01-16	Institut National de la Santé et de la Recherche Médicale	Anticorps à fragments longs anti-neurotensine et anti-neuromédine n et leurs utilisations
WO2025224297A1 (fr)	2024-04-26	2025-10-30	Institut National de la Santé et de la Recherche Médicale	Anticorps ayant une spécificité vis-à-vis de tgfbi et leurs utilisations
WO2025242732A1 (fr)	2024-05-21	2025-11-27	Institut National de la Santé et de la Recherche Médicale	Anticorps pan dirigés contre la protéine de spicule du sars-cov-2 et leurs utilisations à des fins thérapeutiques
WO2025257181A1 (fr)	2024-06-11	2025-12-18	Institut National de la Santé et de la Recherche Médicale	Anticorps ciblant la protéine-43 de liaison à l'adn à réponse trans-active (tdp-43)
WO2025262247A1 (fr)	2024-06-21	2025-12-26	H. Lundbeck A/S	Traitement de troubles de céphalée et/ou de symptômes psychiatriques à l'aide d'anticorps anti-cgrp, et compositions et procédés associés

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6041487A (ja) *	1983-04-25	1985-03-05	ジエネンテツク・インコ−ポレイテツド	酵母発現系でのアルフア因子配列の使用
JPS6229985A (ja) *	1985-06-17	1987-02-07	ジエネツクス・コ−ポレ−シヨン	クロ−ン化プレプロ−ヒト血清アルブミン遺伝子およびヒト血清アルブミン遺伝子、それらの遺伝子を含むプラスミド、プラスミドにより形質転換された微生物、およびその微生物を用いたプレプロ−ヒト血清アルブミン遺伝子の製造方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL66614A (en) *	1981-08-28	1985-09-29	Genentech Inc	Method of constructing a dna sequence encoding a polypeptide,microbial production of human serum albumin,and pharmaceutical compositions comprising it
EP0091527A3 (fr) *	1981-12-14	1984-07-25	The President And Fellows Of Harvard College	Séquences d'ADN, molécules d'ADN recombinant et procédé de préparation de polypeptides du genre de sérumalbumine humaine
JPS6087792A (ja) *	1983-09-23	1985-05-17	ジェネックス・コーポレイション	雑種制御領域
GB8510219D0 (en) *	1985-04-22	1985-05-30	Bass Plc	Isolation of fermentation products
GB8615701D0 (en) *	1986-06-27	1986-08-06	Delta Biotechnology Ltd	Stable gene integration vector
GB8620926D0 (en) *	1986-08-29	1986-10-08	Delta Biotechnology Ltd	Yeast promoter

1987
- 1987-10-30 GB GB878725529A patent/GB8725529D0/en active Pending
1988
- 1988-10-18 ZA ZA888118A patent/ZA888118B/xx unknown
- 1988-10-19 AU AU24046/88A patent/AU619768B2/en not_active Expired
- 1988-10-20 CA CA000580789A patent/CA1341298C/fr not_active Expired - Fee Related
- 1988-10-25 EP EP88310000A patent/EP0322094B1/fr not_active Expired - Lifetime
- 1988-10-25 ES ES88310000T patent/ES2053758T3/es not_active Expired - Lifetime
- 1988-10-25 DE DE8888310000T patent/DE3876401T2/de not_active Expired - Lifetime
- 1988-10-25 AT AT88310000T patent/ATE82858T1/de not_active IP Right Cessation
- 1988-10-28 DK DK198806006A patent/DK175046B1/da not_active IP Right Cessation
- 1988-10-28 HU HU885627A patent/HU209145B/hu unknown
- 1988-10-28 IE IE328088A patent/IE61050B1/en not_active IP Right Cessation
- 1988-10-28 FI FI884993A patent/FI101381B/fi not_active IP Right Cessation
- 1988-10-28 IL IL8822388A patent/IL88223A/en not_active IP Right Cessation
- 1988-10-29 JP JP63272005A patent/JPH02194A/ja active Pending
- 1988-10-31 KR KR1019880014255A patent/KR0153516B1/ko not_active Expired - Lifetime
1992
- 1992-02-14 US US07/944,706 patent/US5380712A/en not_active Expired - Lifetime
1993
- 1993-02-25 GR GR930400399T patent/GR3007162T3/el unknown

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6041487A (ja) *	1983-04-25	1985-03-05	ジエネンテツク・インコ−ポレイテツド	酵母発現系でのアルフア因子配列の使用
JPS6229985A (ja) *	1985-06-17	1987-02-07	ジエネツクス・コ−ポレ−シヨン	クロ−ン化プレプロ−ヒト血清アルブミン遺伝子およびヒト血清アルブミン遺伝子、それらの遺伝子を含むプラスミド、プラスミドにより形質転換された微生物、およびその微生物を用いたプレプロ−ヒト血清アルブミン遺伝子の製造方法

Also Published As

Publication number	Publication date
FI101381B1 (fi)	1998-06-15
FI884993A0 (fi)	1988-10-28
IL88223A0 (en)	1989-06-30
KR890006668A (ko)	1989-06-15
ATE82858T1 (de)	1992-12-15
DK175046B1 (da)	2004-05-10
ZA888118B (en)	1989-07-26
IE883280L (en)	1989-04-30
EP0322094B1 (fr)	1992-12-02
US5380712A (en)	1995-01-10
GR3007162T3 (fr)	1993-07-30
IL88223A (en)	1994-10-07
FI884993L (fi)	1989-05-01
FI101381B (fi)	1998-06-15
KR0153516B1 (ko)	1998-10-15
DE3876401D1 (de)	1993-01-14
HUT47977A (en)	1989-04-28
CA1341298C (fr)	2001-09-25
EP0322094A1 (fr)	1989-06-28
HU209145B (en)	1994-03-28
ES2053758T3 (es)	1994-08-01
GB8725529D0 (en)	1987-12-02
DE3876401T2 (de)	1993-04-22
AU2404688A (en)	1989-05-18
IE61050B1 (en)	1994-09-21
DK600688D0 (da)	1988-10-28
AU619768B2 (en)	1992-02-06
DK600688A (da)	1989-06-21

Publication	Publication Date	Title
KR0153516B1 (ko)	1998-10-15	폴리펩티드
US4845075A (en)	1989-07-04	Biologically active B-chain homodimers
CA2050601C (fr)	2000-09-19	Production d'hemoglobine dans des bacteries et des levures et analogues
JP3390990B2 (ja)	2003-03-31	血清ヒトアルブミン，製剤及び利用
CN1681930B (zh)	2012-09-26	具有包含fivsi基序的信号序列的多肽以及编码该基序的寡核苷酸
CN101166762A (zh)	2008-04-23	白蛋白融合的Kunitz结构域肽
JPH11509525A (ja)	1999-08-24	高純度アルブミンの製造方法
JPS62278A (ja)	1987-01-06	生物学的に活性なｐｄｇｆ類似因子の真核生物細胞内での発現
KR20020008114A (ko)	2002-01-29	방법
US5516896A (en)	1996-05-14	Biologically active B-chain homodimers
JPS63119682A (ja)	1988-05-24	細胞増殖刺激剤
US5218093A (en)	1993-06-08	EGF variants and pharmaceutical use thereof
US5498600A (en)	1996-03-12	Biologically active mosaic proteins
Voss et al.	1994	Periplasmic expression of human interferon-α 2c in Escherichia coli results in a correctly folded molecule
US5527691A (en)	1996-06-18	Expression vectors containing lambdapl promoter and T1 T2 rRNA termination sequence, plasmids containing the vectors, hosts containing the plasmids and related methods
CN102757503A (zh)	2012-10-31	人前列腺凋亡反应蛋白4与凋亡素2配体融合蛋白的制法和用途
US5316919A (en)	1994-05-31	Method of producing 2 KD to 10 KD peptides having no L-methionine residue
JP2869417B2 (ja)	1999-03-10	遺伝子操作により得られるヒト血清アルブミン
Ribó et al.	1996	Production of Human Pancreatic Ribonuclease inSaccharomyces cerevisiaeandEscherichia coli
DE69123242T2 (de)	1997-04-17	Physiologisch aktive Peptide, ihre Verwendung und eine Methode besagte Peptide herzustellen
JPH07119237B2 (ja)	1995-12-20	ヒルジン変異体，その製造法及び抗凝血剤
JPS62181799A (ja)	1987-08-10	発酵工学により製造したカルジオジラチンを含む医薬およびその製造方法
Méndez et al.	1991	Recombinant Yeast as a Production System
JPH0538287A (ja)	1993-02-19	ウサギプレプロ血清アルブミン遺伝子、該遺伝子を含む組換えプラスミドｄｎａ、該組換えプラスミドｄｎａで形質転換された微生物及び該微生物を用いたウサギ血清アルブミンの製造方法
JPH11191A (ja)	1999-01-06	遺伝子操作により得られるヒト血清アルブミン